In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

03/18/2020 05:00 PM EDT

Children experienced reduced pain, improved function, and better overall quality of life.